Home Pharmacy practice NLA 2022 will feature new statin intolerance guidelines, award-winning abstracts, and more.

NLA 2022 will feature new statin intolerance guidelines, award-winning abstracts, and more.

0


Source/Disclosures

Source:

Healio Interviews


Disclosures: Saseen does not report any relevant financial information.


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

The National Lipid Association Science Sessions will be held today through Saturday and will highlight statements on muscle symptoms associated with statins, sessions focused on translational and implementation science, and more.

Healio spoke with the president of the National Lipid Association (NLA) Joseph Saseen, PharmDAssociate Dean for Clinical Affairs, Professor in the Department of Clinical Pharmacy and Department of Family Medicine at Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, on some of this year’s featured topics and what attendees can hope to harvest sessions.


microphone in meeting

Source: Adobe Stock

“It is the right time [for NLA]. Even if we remain on our guard and [COVID-19] precautions in place, like requiring vaccinations, we are all thrilled and excited to have an annual face-to-face live meeting again,” Saseen told Healio. “Our desire with our scientific sessions to have content that applies to our diverse population of members, which includes clinical pharmacists, dietitians, nurses, physicians, physician assistants and clinical scientists…and many of our sessions convey this broad perspective.

Joseph Saeen

“Our opening session will focus on assessing the evidence supporting non-statin treatment in patients with statin-associated muscle symptoms,” said Saseen. “We’re going to use a fun approach where we have four people presenting evidence with four different treatment options and then we’re going to discuss a case presentation broadly and use audience polls and panel discussions to spice it all up.”

The NLA’s keynote session, “Expert Analysis: Evidence Supporting Non-Statin Therapies in a Patient with Statin-Associated Muscle Symptoms (SAMS),” will take place today at 4:00 p.m. MST.

“Another thing that you might not see in many sessions is this session on translating evidence into practice or translational or implementation science on Friday morning,” Saseen told Healio. “It reviews things like effective communication strategies, optimizing your electronic health record, and using new approaches to improve care, not just of an individual patient, but of your patient population. .

On Saturday, three last-minute clinical trials will be presented:

  • Apolipoprotein B and lipoprotein (a) in atherosclerotic cardiovascular disease risk categories in Hispanic/Latino people residing in the United States: results from the Hispanic Community Health Study/Latino Study (HCHS/SOL) – presented by Parag H. Joshi, MD, MHS;
  • Obicetrapib lowers LDL-C in patients taking high-intensity statins – Results from the ROSE clinical trial – presented by Michael H. Davidson, MD, FACC, FNLA; and
  • Reduction of ischemic events, including cardiovascular mortality, with icosapent ethyl in patients with a history of myocardial infarction: REDUCE-IT PRIOR MI – presented by Prakriti Gaba, MD.

“We also have our science abstracts where we hope to present cutting-edge science, but we have a lot of our other sessions,” Saseen told Healio. “We have sessions aimed at clinicians, such as different perspectives on treatment options; session on drug-related misadventures; we have a Diversity, Equity and Inclusion (DEI) session to give our audience members tips on how to improve their DEI efforts, whether it’s a training program or providing more IED-focused wellness care.

Among nearly 40 scientific abstracts that will be presented during NLA, the following four will be oral presentations:

  • Universal screening for familial hypercholesterolemia in two populations – presented by Urh Groselj, MD;
  • A Novel ABCG8 Variant and Apo(A) Short Isoform Associated with Premature Atherosclerosis and Familial Hypercholesterolemia Phenocopy – presented by Loba Alam, MD;
  • An unresolved case: HF or sitosterolemia? – presented by Juliette Logan, MD, the first Young Investigator Award winner and first oral presenter; and
  • Gender Disparities in Familial Hypercholesterolemia Treatment and Outcomes – presented by Amanda Guerin, BScDonald Hunninghake, MD, Familial Hypercholesterolemia Award Winner

“Maybe the icing on the cake is that we’re going to have a session called science statements, and we’re going to release our science statement on statin intolerance, which we’re really excited about. Journal of Clinical Pathology that morning,” Saseen told Healio.

The statement on statin intolerance will be presented by Kevin C. Maki, PhD, CLS, FNLA, the new president of the ALN, Saturday at 9 a.m. MST.

Also presented will be a scientific statement titled “Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement from the American Heart Association”. This statement will be presented by P. Barton Duell, MD, FNLA, Saturdays at 9:30 a.m. MST.

Healio is a media partner of the NLA Scientific Sessions. The Healio team will provide coverage of the meeting, including reports on the above sessions and more. Follow this link and on Twitter at @CardiologyToday. For more information about the NLA, visit www.lipid.org/meetings/sessions/home.